← Back to headlines
Lundbeck's Migraine Drug Sales Drive Growth
Danish pharmaceutical company Lundbeck reported an 11 percent increase in revenue to 13.6 billion kroner in the first half of the year, primarily driven by sales of its migraine medication.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Universal Studios Japan Announces Nearly $2 Billion Expansion Project
19m ago
Nvidia Reports Strong Q2 Earnings Driven by AI Demand Surge
35m ago
Nvidia Stock Rises as Bank of America Doubles Down on Bullish Forecast
40m ago
Canada Removes US Seafood from Retaliatory Tariff List Amid Trade Tensions
52m ago